Intragastric Balloon Market, By Product Type (Single Balloon, Dual Balloon, Triple Balloon, and Others), By Filling Material (Saline Filled and Gas Filled), By End User (Hospitals, Ambulatory Surgical Centers, and Clinics), By Distribution Channel (Online Pharmacies, Retail Pharmacies, and Hospital Pharmacies), By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

Published In : Dec 2023

Code : CMI6421

Pages :140

Formats :

Excel and PDF

Industry : Medical Devices

Market News

Recent Developments:

On June 23, 2023, Allurion technologies, a medical device company announced that it has signed a 12-month pilot collaboration agreement with Medtronic, a global leader in medical technology, services, and solutions. Under the terms of their deal, Medtronic will be able to offer Allurion’s swallowable gastric balloon and artificial intelligence-powered Iris healthcare management program through its existing sales channels in Central and Eastern Europe and the Middle East and Africa.
In October 2022, Allurion received approval to launch its revolutionary gastric balloon technology in Brazil. The Allurion Balloon, known in Brazil as the Elipse Balloon, is the first and only intragastric weight-loss balloon that is routinely placed and removed without surgery, endoscopy, or anesthesia.
In September 2022, Allurion launched its swallowable gastric balloon capsule for weight loss in India. During the press conference, the company informed that it is the only medical weight-loss device fully approved by the Central Drugs Standard Control Organisation (CDSCO).
In January 2022, Apollo Endosurgery, an industry pioneer and leader in advance therapeutic endoscopy received U.S. FDA approval for its Orbera365 Managed Weight Loss System, the first intragastric balloon with an indication for weight loss therapy of up to 12 months. This enhanced system can help patients achieve and maintain weight loss goals.
In June 2021, Spatz3, a new dual intragastric balloon system by Spatz FGIA, a medical device manufacturing company received CE mark approval. It is designed to remain in the stomach for up to 12 months to induce early satiety and help with weight loss.
In July 2020, Allurion Technologies, a pioneering leader in the development of innovative, scalable, and trusted weight loss experiences, announced entry into Asia Pacific with the launch of the Elipse Program in Hong Kong, Malaysia, and Singapore. Building upon its success in Europe, the Middle East, and Latin America, the company’s entry into Asia Pacific could impact the lives of over 1 billion people who are overweight or obese in a region that historically has had limited access to non-invasive weight loss treatments
In May 2019, Allurion Technologies launched Allurion Virtual Care Suite, a digital health platform to support patients before and after the Elipse gastric balloon procedure. This can improve patient outcomes.